Disease Domain | Count |
---|---|
Neoplasms | 14 |
Infectious Diseases | 4 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 8 |
Antibody drug conjugate (ADC) | 6 |
Antibody | 2 |
Bispecific T-cell Engager (BiTE) | 1 |
Cell therapy | 1 |
Target |
Mechanism PfCSP inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseEarly Phase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date11 Feb 2020 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
APN-850297 | COVID-19 More | Early Phase 1 |
APN-987481 | Stomach Cancer More | Preclinical |
MAM-01 ( PfCSP ) | Malaria More | Preclinical |
APN-497444 | Neoplasms More | Preclinical |
APN-541885 ( IL-15 ) | Neoplasms More | Preclinical |